EXEL vs. SYNH, PRAH, CRL, MEDP, NRC, ALNY, BMRN, NBIX, INCY, and UTHR
Should you be buying Exelixis stock or one of its competitors? The main competitors of Exelixis include Syneos Health (SYNH), PRA Health Sciences (PRAH), Charles River Laboratories International (CRL), Medpace (MEDP), National Research (NRC), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), Incyte (INCY), and United Therapeutics (UTHR).
Exelixis (NASDAQ:EXEL) and Syneos Health (NASDAQ:SYNH) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.
Exelixis has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, Syneos Health has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500.
Exelixis has a net margin of 11.10% compared to Syneos Health's net margin of 1.31%. Exelixis' return on equity of 8.85% beat Syneos Health's return on equity.
Exelixis received 31 more outperform votes than Syneos Health when rated by MarketBeat users. Likewise, 68.16% of users gave Exelixis an outperform vote while only 64.43% of users gave Syneos Health an outperform vote.
85.3% of Exelixis shares are held by institutional investors. Comparatively, 91.2% of Syneos Health shares are held by institutional investors. 2.9% of Exelixis shares are held by company insiders. Comparatively, 0.3% of Syneos Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Exelixis presently has a consensus price target of $26.13, indicating a potential upside of 18.37%. Given Exelixis' higher possible upside, equities analysts clearly believe Exelixis is more favorable than Syneos Health.
Syneos Health has higher revenue and earnings than Exelixis. Exelixis is trading at a lower price-to-earnings ratio than Syneos Health, indicating that it is currently the more affordable of the two stocks.
In the previous week, Exelixis had 14 more articles in the media than Syneos Health. MarketBeat recorded 14 mentions for Exelixis and 0 mentions for Syneos Health. Exelixis' average media sentiment score of 1.08 beat Syneos Health's score of 0.00 indicating that Exelixis is being referred to more favorably in the media.
Summary
Exelixis beats Syneos Health on 11 of the 17 factors compared between the two stocks.
Get Exelixis News Delivered to You Automatically
Sign up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EXEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Exelixis Competitors List
Related Companies and Tools
